{
    "id": 17517,
    "fullName": "OSBPL3 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "OSBPL3 positive indicates the presence of the OSBPL3 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 26031,
        "geneSymbol": "OSBPL3",
        "terms": [
            "OSBPL3",
            "ORP-3",
            "ORP3",
            "OSBP3"
        ]
    },
    "variant": "positive",
    "createDate": "02/01/2016",
    "updateDate": "01/20/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4331,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase II trial, FMO4/OSBPL3 expression was associated with favorable overall survival in recurrent glioblastoma patients treated with a combination of Avastin (bevacizumab) and Lomustine (PMID: 26762204).",
            "molecularProfile": {
                "id": 17816,
                "profileName": "FMO4 pos OSBPL3 pos"
            },
            "therapy": {
                "id": 2118,
                "therapyName": "Bevacizumab + Lomustine",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4498,
                    "pubMedId": 26762204,
                    "title": "Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26762204"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17815,
            "profileName": "OSBPL3 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17816,
            "profileName": "FMO4 pos OSBPL3 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}